Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

Research and Innovation Action · Running

GENEGUT Oral delivery of encapsulated RNA nanotherapeutics for targeted treatment of ileal Crohn's disease

Coordinator
University College Cork - National University of Ireland, Cork, Ireland
Runs
1 October 2022 to 30 September 2026
Status
Running
EU funding
€4.6m
Total cost
€4.6m
Partners
9 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101057491

What the project is doing

In the project's own words, from its summary on CORDIS.

Crohn’s disease is a non-communicable, global disease with an accelerating incidence (up to 23 per 100,000 persons/year) and annual health costs in excess of 5 billion euro in Europe. Despite advances in new immune modulators and biological treatment, up to 30% of patients become non-responders, highlighting the pressing need for novel, advanced therapies. GENEGUT will transform treatment of ileal Crohn’s disease (CD) by developing a first-in-class oral RNA-based therapy, tackling inflammation locally in the intestinal tissue, while avoiding systemic side effects.

The success of mRNA covid vaccines demonstrated the potential of RNA-based therapies; the challenge is to extend this revolutionary therapeutic modality to non-communicable diseases where RNA delivery has not been achieved, such as ileal CD. Delivery of RNA will be enabled by a combination approach where novel biomaterials, including amphiphilic cyclodextrins and amino polyesters (both patented by partners), designed to overcome the barriers in the gastrointestinal tract will complex the RNA within nanoparticles (NPs).

Our industry partner’s novel capsule technology will ensure site-specific release of the encapsulated NPs at the diseased ileum. The RNA-nanotherapeutics (siRNA and mRNA) will modulate gene expression locally in the ileum by targeting the clinically validated (JAK/STAT) pathway and two exploratory targets, Gremlin and Adrenomedullin. Proof-of-efficacy will be demonstrated in vivo and also in a 3D multi-cellular model of ileal CD using primary human cells.

GENEGUT brings together 9 partners from 8 European countries covering the lifecycle from bench to bedside, creating a network of renowned researchers, expert clinical scientists, SMEs and larger pharma companies and a patient organisation. GENEGUT will result in an oral RNA therapeutic ready for early clinical trial including coherent plans for clinical trials and regulatory submission thus enabling rapid availability for patients.

Topics

Who is involved

OrganisationCityCountryRole
University College Cork - National University of Ireland, CorkCorkIrelandCoordinator
International Federation of Crohn's and Ulcerative Colitis AssociationsBruxelles / BrusselBelgiumParticipant
Janssen Pharmaceutica NVBeerseBelgiumParticipant
Accelopment Schweiz AGZurichSwitzerlandAssociatedpartner
Capsugel France SASColmarFranceParticipant
Carbohyde Zartkoruen Mukodo ReszvenytarsasagBudapestHungaryParticipant
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do PortoPortoPortugalParticipant
Uppsala UniversitetUppsalaSwedenParticipant
Bangor UniversityBangorUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI